KPV
KPV (Lysine-Proline-Valine) is a master anti-inflammatory tripeptide, naturally derived as the C-terminal amino acid sequence of alpha-Melanocyte Stimulating Hormone (α-MSH). It acts as a profound cellular fire-retardant, obliterating rampant systemic inflammation at the deepest genetic level without causing dangerous immunosuppression or unwanted skin pigmentation. Because it is highly stable, it has become a staple for aggressively treating massive inflammatory bowel diseases (IBD, Crohn's), chronic psoriasis, and severe mucosal tissue degradation via oral, topical, or systemic administration.
Quick Stats
Scientific Data
Mechanism of Action
KPV (Lysine-Proline-Valine) is the C-terminal tripeptide of alpha-melanocyte stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the full α-MSH peptide while offering much smaller size (enabling oral/topical delivery) and eliminating pigmentation effects.
KPV activates melanocortin receptors (MC1R, MC3R) in intestinal epithelial cells, macrophages, and T-cells, suppressing NF-κB and pro-inflammatory cytokine cascades (IL-1β, TNF-α, IL-6). It has been specifically studied for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, where gut delivery of anti-inflammatory peptides is especially challenging.
Source: PMID: 10817504
Background & History
KPV (Lys-Pro-Val) is a tripeptide derived from the C-terminus of alpha-MSH (α-MSH) that retains the anti-inflammatory potency of the parent peptide without its melanogenic effects. Developed by researchers at Harvard Medical School (Bhardwaj et al., 1996), it was shown to penetrate cells and interact directly with NF-κB components to reduce inflammatory cytokine production. Its small size enables unique tissue penetration including the GI mucosa, making it particularly relevant for intestinal inflammatory conditions.
Research Use Cases
- ✓Inflammatory bowel disease: Crohn's disease and ulcerative colitis
- ✓Skin inflammation: psoriasis, eczema, wound healing
- ✓Reducing systemic inflammatory markers (IL-6, TNF-α, NF-κB)
- ✓Post-infection or post-surgical inflammatory resolution
Dosing Protocol
| Typical Dose | 200-500 mcg/day |
| Frequency | 1-2× daily (or topical/oral) |
| Half-Life | ~30 minutes (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
Dosing Protocols
IBD / Gut Inflammation (oral)
Systemic Anti-Inflammation (SubQ)
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 200–500 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 154 mcg | 270 mcg | 386 mcg |
| 140 lb(63 kg) | 180 mcg | 315 mcg | 450 mcg |
| 160 lb(73 kg) | 209 mcg | 365 mcg | 521 mcg |
| 180 lb(82 kg) | 234 mcg | 410 mcg | 586 mcg |
| 200 lb(91 kg) | 260 mcg | 455 mcg | 650 mcg |
| 220 lb(100 kg) | 286 mcg | 500 mcg | 714 mcg |
| 250 lb(113 kg) | 323 mcg | 565 mcg | 807 mcg |
💉 For exact syringe units based on your vial concentration, use the KPV Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
IBD / Gut Inflammation
LowPreclinical data very promising for Crohn's and UC. Can be delivered directly to gut mucosa orally.
Systemic Anti-Inflammation
LowBroad anti-inflammatory cytokine suppression via melanocortin pathway. Research peptide status.
Reconstitution Example
Safety & Considerations
Derived from endogenous α-MSH C-terminus. Very favorable safety profile. Tripeptide — rapidly metabolized. No known toxicity at research doses. Oral and topical forms generally well-tolerated.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Anti-inflammatory mechanism — may reduce effectiveness of pro-inflammatory vaccines if taken in close proximity to immunization. No significant drug interactions documented at research doses. Oral bioavailability in GI conditions makes it uniquely suited for intestinal applications without systemic injection.
Synergies & Common Stacks
KPV suppresses the inflammatory cascade; BPC-157 repairs the tissue damage from that inflammation. Powerful combination for GI healing protocols (IBD, leaky gut).
LL-37 antimicrobial + KPV anti-inflammatory — a comprehensive mucosal defense and repair stack.
Featured In Clinical Protocols
Gut Repair & Microbiome Restoration
Repair intestinal permeability (leaky gut), eliminate systemic inflammation, and restore microbiome balance using localized gastric regenerative peptides.
Immune Resilience & Post-Viral Stack
Modulate robust T-cell activation, balance Th1/Th2 responses, and shield against viral pathogenesis through thymic regeneration.
Dosing Quick Reference
Frequently Asked Questions
Can KPV be taken orally for IBD?▼
How does KPV compare to BPC-157 for gut inflammation?▼
References
- Kannengiesser K et al. “"Alpha-MSH tripeptide (KPV) inhibits colitis via melanocortin signaling".” Gut (2008). PMID: 18319299
Get KPV from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.
Affiliate link · Full review